Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Edwards To Contact Him Directly To Discuss Their OptionsIf you suffered losses exceeding $100,000 in Edwards between February 6, 2024 and July 24, 2024 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).[You may also click here for additional information]NEW YORK, Oct. 25, 2024 /PRNewswire ...

Edwards Lifesciences Corporation (EW) reported third-quarter 2024 adjusted earnings per share (EPS) of 67 cents, in line with the Zacks Consensus Estimate. The figure increased 21.8% from the year-ago quarter's level. On this note, GAAP EPS from continuing operations was 61 cents compared with 55 cents in the third quarter of 2023. The quarter's one-time adjustments primarily include certain litigation expenses and amortization of intangible assets. In the quarter, the company completed the sale of Critical ...

Financial Data and Key Metrics Changes - The company reported third quarter sales from continuing operations of $1.35 billion, reflecting a 9.6% underlying sales growth [20][21] - Adjusted earnings per share for the quarter was $0.67, slightly ahead of expectations [20] - The adjusted gross profit margin was elevated at 80.7%, slightly higher year-over-year and sequentially [22][23] - The company expects fourth quarter gross margin to align with the high end of its full year guidance range of 76% to 78% [22][62] Business Line Data and Key Metrics Changes - TAVR global sales reached $1 billion in the third quarter, increasing 6% when adjusted for currency [8][12] - TMTT sales were $91 million, representing a 74% growth over the prior year, driven by PASCAL growth globally [14] - Surgical sales from continuing operations were $240 million, increasing 5% over the prior year [16] Market Data and Key Metrics Changes - In the U.S., TAVR sales growth was in line with global growth, with hospitals exploring investments to address future workflow needs [10][12] - In Europe, the market position improved sequentially, supported by the launch of SAPIEN 3 Ultra RESILIA [11] - Japan experienced slower market growth, impacting results, but the company remains focused on addressing under-treatment of AS [11] Company Strategy and Development Direction - The company aims to position TAVR for long-term growth through differentiated technologies and global initiatives [6][7] - New therapeutic areas such as aortic regurgitation and implantable heart failure management are being explored [7][18] - The company is committed to expanding its portfolio and driving sustainable growth through innovative therapies [7][27] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the long-term growth opportunities driven by innovative therapies and strong clinical evidence [27] - The company anticipates challenges in the fourth quarter due to one-time items and fewer selling days compared to the third quarter [26] - Management remains optimistic about the ability of hospitals to scale and support trans-catheter procedure growth over time [10][46] Other Important Information - The company closed the sale of critical care in September, which impacted financial results [21] - The company repurchased $1 billion of stock during the third quarter, with approximately $1.4 billion remaining under its share repurchase authorization [25] - The company expects to provide detailed 2025 financial guidance at an investor conference in December [26] Q&A Session Summary Question: Clarification on Q4 guidance and EPS - Management indicated that the elimination of critical care impacted earnings per share by about $0.35, along with additional expenses from acquisitions [30][32] Question: Impact of hurricanes and China on Q4 guidance - Management clarified that the China adjustment was a one-time rebate and that there are three fewer selling days in Q4 compared to Q3 [35][36] Question: Competitive dynamics and market share - Management acknowledged the competitive landscape but emphasized the strength of their clinical evidence and technology, maintaining a premium pricing strategy [71][72] Question: Updates on EVOQUE and NCD - Management is optimistic about the NCD process for EVOQUE and expects a draft by year-end, with full support for CMS efforts [50][51]

Edwards Lifesciences (EW) reported $1.35 billion in revenue for the quarter ended September 2024, representing a year-over-year decline of 8.5%. EPS of $0.67 for the same period compares to $0.59 a year ago. ...

RADNOR, Pa., Oct. 24, 2024 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed in the United States District Court for the Central District of California against Edwards Lifesciences Corporation (“Edwards”) (NYSE: EW) on behalf of investors who purchased or otherwise acquired Edwards securities between February 6, 2024 and July 24, 2024, inclusive (the “Class Period”) The lead plaintiff deadline is Dece ...

Sales Performance - Q3 sales from continuing operations grew 9%, with constant currency sales growing 10%[2] - TAVR sales reached $1.0 billion, growing 6% year-over-year, with stable pricing globally[3] - TMTT sales surged 73%, driven by the PASCAL and EVOQUE commercial launches[2] - Net sales for the three months ended September 30, 2024, were $1,354.4 million, a 8.9% increase from $1,243.4 million in the same period of 2023[18] - Total sales for Q3 2024 reached $1,354.4 million, an increase of $111.0 million or 8.9% compared to Q3 2023[32] - Transcatheter Aortic Valve Replacement sales were $1,023.3 million, reflecting a GAAP growth rate of 6.5%[32] - Transcatheter Mitral and Tricuspid Therapies experienced a significant growth of 73.4%, with sales of $91.1 million in Q3 2024[32] - Year-to-date sales for 2024 totaled $4,053.7 million, up $310.1 million or 8.3% from the same period in 2023[32] - Sales in the United States for YTD 2024 were $2,393.1 million, representing an 8.6% growth rate[32] - Europe sales for YTD 2024 increased by 11.4% to $978.0 million[32] - Outside of the United States, sales reached $1,660.6 million, reflecting a growth rate of 7.8%[32] Financial Metrics - Adjusted EPS for Q3 was $0.67, slightly above the company's guidance[8] - Gross profit margin for Q3 was 80.7%, up from 79.9% in the same period last year[8] - Operating income for the three months ended September 30, 2024, was $350.6 million, a decrease from $365.9 million in the same period of 2023[18] - Net income attributable to Edwards Lifesciences Corporation for the three months ended September 30, 2024, was $3,070.8 million, compared to $384.9 million in the same period of 2023[18] - Basic earnings per share for continuing operations were $0.61 for the three months ended September 30, 2024, compared to $0.55 in the same period of 2023[18] - The effective tax rate for the three months ended September 30, 2024, was 10.1%, down from 13.6% in the same period of 2023[18] - The gross profit margin improved to 80.6% in Q3 2024, up from 79.8% in Q3 2023[26][27] - Operating income for Q3 2024 was $350.6 million, compared to $365.9 million in Q3 2023, indicating a decrease of 4.5%[26][27] - Net income attributable to Edwards Lifesciences Corporation for Q3 2024 was $363.5 million, an increase from $336.1 million in Q3 2023, reflecting a growth of 8.2%[26][27] - Diluted EPS for Q3 2024 was $0.61, compared to $0.55 in Q3 2023, marking an increase of 10.9%[26][27] Expenses and Investments - Research and development expenses rose 4% to $253 million, representing 18.7% of sales[8] - Research and development expenses for the three months ended September 30, 2024, were $253.4 million, up from $242.8 million in the same period of 2023[18] - The company recorded restructuring expenses of $32.9 million in the third quarter of 2024 related to global workforce realignment[23] - Non-GAAP adjustments for litigation expenses in Q3 2024 amounted to $10.8 million, while restructuring expenses were $32.9 million[26] - The company reported a charitable contribution of $30.0 million to the Edwards Lifesciences Foundation in the third quarter of 2024[23] - The company reported a charitable foundation contribution of $30.0 million in Q3 2024, which impacted net income[26] Guidance and Future Outlook - Full year sales growth guidance remains unchanged at 8% to 10%, with Q4 sales expected between $1.33 billion and $1.39 billion[10] - Management expects to provide guidance for sales and sales growth rates on a "constant currency basis" to enhance comparability with historical results[21]

NEWTOWN, Pa., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Edelson Lechtzin LLP, a leading class action law firm, announces the filing of a securities fraud class action on behalf of all purchasers of Edwards Lifesciences Corporation securities (NYSE: EW) between February 6, 2024, and July 24, 2024, inclusive (the “Class Period”). To join this case, go HERE. Investors who purchased Edwards stock during the Class Period may move the U.S. District Court for the Central District of California to appoint them as the lead ...

Core Viewpoint - A class action lawsuit has been filed against Edwards Life Sciences Corporation, alleging violations of federal securities laws related to misleading statements about its Transcatheter Aortic Valve Replacement (TAVR) platform and its financial performance during the class period from February 6, 2024, to July 24, 2024 [1][3]. Group 1: Lawsuit Details - The lawsuit represents all individuals and entities that purchased Edwards securities during the specified class period and claims that the company and certain executives made materially false and misleading statements [1][3]. - Investors have until December 13, 2024, to seek appointment as lead plaintiff in the class action lawsuit [1]. Group 2: Company Background - Edwards Life Sciences is an international company focused on researching, developing, and providing products and technologies for heart valve repair and replacement therapies, as well as critical care monitoring solutions [3]. Group 3: Allegations and Financial Impact - The lawsuit alleges that the defendants concealed material adverse facts regarding the TAVR platform, emphasizing their commitment and confidence in its demand in lower-penetrated markets [3]. - On July 24, 2024, Edwards reported disappointing second-quarter financial results and reduced its revenue guidance for the TAVR platform, attributing the poor performance to increased pressure on hospital workflows from the growth of structural heart therapies [4]. - Following the announcement of these results, Edwards's stock price fell by $27.25 per share, representing a nearly 32% decline [4].

RADNOR, Pa., Oct. 23, 2024 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against Edwards Lifesciences Corporation ("Edwards") (NYSE: EW) on behalf of investors who purchased or otherwise acquired Edwards securities between February 6, 2024 and July 24, 2024, inclusive (the "Class Period") The lead plaintiff deadline is December 13, 2024.CONTACT KESSLER TOPAZ MELTZER & CHECK, LLP:If you suffered Edward ...

NEW YORK, Oct. 23, 2024 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Edwards Lifesciences Corporation (NYSE: EW). Shareholders who purchased shares of EW during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/edwards-lifesciences-loss-submission-form/?id=109173&from=3 CLASS PERIO ...